Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.016 | 0 | 0.5 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.016 | 0 | 0.5 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.016 | 0 | 0.5 |
Toxoplasma gondii | PAN domain-containing protein | 0.0318 | 0.5245 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0 | 0.5 |
Echinococcus granulosus | enteropeptidase | 0.0462 | 1 | 1 |
Echinococcus multilocularis | enteropeptidase | 0.0462 | 1 | 1 |
Echinococcus granulosus | glycoprotein Antigen 5 | 0.0462 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0 | 0.5 |
Echinococcus multilocularis | Mastin | 0.0462 | 1 | 1 |
Schistosoma mansoni | subfamily S1A unassigned peptidase (S01 family) | 0.0462 | 1 | 1 |
Toxoplasma gondii | PAN domain-containing protein | 0.0318 | 0.5245 | 1 |
Onchocerca volvulus | Arrow homolog | 0.016 | 0 | 0.5 |
Echinococcus multilocularis | glycoprotein Antigen 5 | 0.0462 | 1 | 1 |
Brugia malayi | Fibulin-1 precursor | 0.016 | 0 | 0.5 |
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.016 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0 | 0.5 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.016 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.016 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | = 47.7 % | Inhibition of human MDR1 expressed in MDCK2 cells assessed as increase of rhodamine 123 uptake at 30 uM up to 240 mins relative to 5 uM tariquidar | ChEMBL. | 25740634 |
T1/2 (ADMET) | = 19 min | Half life in BALB/c mouse liver microsomes at 1 uM in presence of NADPH by HPLC-MS/MS method | ChEMBL. | 25740634 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.